Evidence map›Paper›PMID 29804270›Full record

ArticleJournal of endocrinological investigation2019

Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?

M Demirpence, A Guler, H Yilmaz, A Sayin, Y Pekcevik, H Turkon, A Colak, E M Ari, B Aslanipour, G U Kocabas and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Role of Urotensin-II in Saphenous Vein Graft Disease.Brazilian journal of cardiovascular surgery · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

M DemirpenceDivision of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Tepecik Training and Research Hospital, Tepecik, 35120, Izmir, Turkey.
A GulerDepartment of Family Physician, Izmir Bozyaka Training and Research Hospital, Bozyaka, 35170, Izmir, Turkey.
H YilmazDivision of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Tepecik Training and Research Hospital, Tepecik, 35120, Izmir, Turkey.
A SayinDepartment of Cardiology, Izmir Tepecik Research and Training Hospital, Tepecik, 35120, Izmir, Turkey.
Y PekcevikDepartment of Radiology, Izmir Tepecik Training and Research Hospital, Tepecik, 35120, Izmir, Turkey.
H TurkonDepartment of Medical Biochemistry, Faculty of Medicine, Canakkale Onsekiz Mart University, 17120, Canakkale, Turkey.
A ColakDepartment of Clinical Biochemistry, Izmir Tepecik Training and Research Hospital, Tepecik, 35120, Izmir, Turkey.
E M AriDepartment of Clinical Biochemistry, Izmir Tepecik Training and Research Hospital, Tepecik, 35120, Izmir, Turkey.
B AslanipourDepartment of Bioengineering, Faculty of Engineering, Ege University, Bornova, 35100, Izmir, Turkey.
G U KocabasDivision of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Bozyaka, 35170, Izmir, Turkey.
M CalanDivision of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Bozyaka, 35170, Izmir, Turkey. drmehmetcalan@gmail.com.
Izmir Tepecik Eğitim ve Araştırma Hastanesi · TRIzmir Bozyaka Eğitim ve Araştırma Hastanesi · TRÇanakkale Onsekiz Mart Üniversitesi · TREge University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAcromegaly is a rare disorder existed in the result of overproduction of growth hormone (GH). The disorder is associated with increased cardiovascular risk factors and metabolic abnormalities. Urotensin II (UII), a secreted vasoactive peptide hormone, belonging somatostatin superfamily, plays an essential role in atherosclerosis and glucose metabolism. The aim of this study was to ascertain whether circulating UII levels are altered in subjects with acromegaly, and to describe the relationship between UII and hormonal or cardiometabolic parameters.

methodsThis cross-sectional study included 41 subjects with active acromegaly, 28 subjects with controlled acromegaly, and 37 age- and BMI-matched controls without acromegaly. Hormonal and metabolic features of the subjects as well as carotid intima media thickness (cIMT) and epicardial fat thickness (EFT) were defined. Circulation of UII levels was determined via ELISA.

resultsBoth active and controlled acromegalic subjects showed a significant elevation of circulating levels of UII with respect to controls. There was no remarkable difference in circulating levels of UII between active and controlled acromegalic groups. Both cIMT and EFT were remarkably increased in acromegaly subjects comparing to controls. UII positively correlated with cIMT, EFT, BMI, and HOMA-IR. There was no correlation between UII and GH, insulin-like growth factor-1. According to the results obtained from regression models, UII levels independently predicted cIMT and EFT.

conclusionElevated UII levels are associated with severity of cardiovascular risk factors including cIMT and EFT in acromegalic subjects.

Indexed as

AcromegalyAdultBiomarkersCardiovascular DiseasesCarotid Intima-Media ThicknessCross-Sectional StudiesFemaleHumansInsulin ResistanceMaleMiddle AgedPrognosisRisk FactorsUrotensinsBiomarkersurotensin IIUrotensinsAcromegalyCarotid intima media thicknessEpicardial fat thicknessInsulin resistanceUrotensin II

Identifiers

PMID29804270
OpenAlexW2803990321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.